INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25701, 10487, 'Simvastatin', 'Diabetes Mellitus', 'Increases in HbA1c and fasting serum glucose levels have been reported with the use of certain HMG-CoA reductase inhibitors.  Caution should be exercised when using these agents in diabetic patients and close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25702, 14073, 'Simvastatin', 'Diabetes Mellitus', 'Increases in HbA1c and fasting serum glucose levels have been reported with the use of certain HMG-CoA reductase inhibitors.  Caution should be exercised when using these agents in diabetic patients and close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25703, 14074, 'Simvastatin', 'Diabetes Mellitus', 'Increases in HbA1c and fasting serum glucose levels have been reported with the use of certain HMG-CoA reductase inhibitors.  Caution should be exercised when using these agents in diabetic patients and close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25704, 22079, 'Simvastatin', 'Diabetes Mellitus', 'Increases in HbA1c and fasting serum glucose levels have been reported with the use of certain HMG-CoA reductase inhibitors.  Caution should be exercised when using these agents in diabetic patients and close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25705, 22772, 'Simvastatin', 'Diabetes Mellitus', 'Increases in HbA1c and fasting serum glucose levels have been reported with the use of certain HMG-CoA reductase inhibitors.  Caution should be exercised when using these agents in diabetic patients and close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25706, 27011, 'Simvastatin', 'Diabetes Mellitus', 'Increases in HbA1c and fasting serum glucose levels have been reported with the use of certain HMG-CoA reductase inhibitors.  Caution should be exercised when using these agents in diabetic patients and close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25707, 27012, 'Simvastatin', 'Diabetes Mellitus', 'Increases in HbA1c and fasting serum glucose levels have been reported with the use of certain HMG-CoA reductase inhibitors.  Caution should be exercised when using these agents in diabetic patients and close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25708, 27021, 'Simvastatin', 'Diabetes Mellitus', 'Increases in HbA1c and fasting serum glucose levels have been reported with the use of certain HMG-CoA reductase inhibitors.  Caution should be exercised when using these agents in diabetic patients and close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25709, 29985, 'Simvastatin', 'Diabetes Mellitus', 'Increases in HbA1c and fasting serum glucose levels have been reported with the use of certain HMG-CoA reductase inhibitors.  Caution should be exercised when using these agents in diabetic patients and close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25710, 29986, 'Simvastatin', 'Diabetes Mellitus', 'Increases in HbA1c and fasting serum glucose levels have been reported with the use of certain HMG-CoA reductase inhibitors.  Caution should be exercised when using these agents in diabetic patients and close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25711, 29987, 'Simvastatin', 'Diabetes Mellitus', 'Increases in HbA1c and fasting serum glucose levels have been reported with the use of certain HMG-CoA reductase inhibitors.  Caution should be exercised when using these agents in diabetic patients and close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25712, 0, 'Sipuleucel-T', 'Thromboembolism', 'The use of sipuleucel-T can cause thromboembolism, including deep venous thrombosis and pulmonary embolism.  It is recommended to exercise caution when using this agent in patients with risk factors for thromboembolic events.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25713, 0, 'Sipuleucel-T', 'Cerebrovascular Disorders', 'Vascular disorders that include, cerebrovascular and cardiovascular events have occurred with the use of sipuleucel-T.  It is recommended to exercise caution when using this agent in patients with risk factors for vascular disorders such as, hemorrhagic and ischemic strokes, and myocardial infarctions.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25714, 84, 'Semaglutide', 'Mental Disorders', 'The use of semaglutide (Wegovy) for weight loss should be avoided in patients with a history of suicidal attempts or active suicidal ideation.  Suicidal behavior and ideation have been reported in clinical trials with other weight management products.  If used, monitor patients for the emergence or worsening of depression, suicidal thoughts or behaviors, and/or any unusual changes in mood or behavior.  Discontinue use in patients who experience suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25715, 271, 'Semaglutide', 'Mental Disorders', 'The use of semaglutide (Wegovy) for weight loss should be avoided in patients with a history of suicidal attempts or active suicidal ideation.  Suicidal behavior and ideation have been reported in clinical trials with other weight management products.  If used, monitor patients for the emergence or worsening of depression, suicidal thoughts or behaviors, and/or any unusual changes in mood or behavior.  Discontinue use in patients who experience suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25716, 6996, 'Semaglutide', 'Mental Disorders', 'The use of semaglutide (Wegovy) for weight loss should be avoided in patients with a history of suicidal attempts or active suicidal ideation.  Suicidal behavior and ideation have been reported in clinical trials with other weight management products.  If used, monitor patients for the emergence or worsening of depression, suicidal thoughts or behaviors, and/or any unusual changes in mood or behavior.  Discontinue use in patients who experience suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25717, 7537, 'Semaglutide', 'Mental Disorders', 'The use of semaglutide (Wegovy) for weight loss should be avoided in patients with a history of suicidal attempts or active suicidal ideation.  Suicidal behavior and ideation have been reported in clinical trials with other weight management products.  If used, monitor patients for the emergence or worsening of depression, suicidal thoughts or behaviors, and/or any unusual changes in mood or behavior.  Discontinue use in patients who experience suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25718, 7545, 'Semaglutide', 'Mental Disorders', 'The use of semaglutide (Wegovy) for weight loss should be avoided in patients with a history of suicidal attempts or active suicidal ideation.  Suicidal behavior and ideation have been reported in clinical trials with other weight management products.  If used, monitor patients for the emergence or worsening of depression, suicidal thoughts or behaviors, and/or any unusual changes in mood or behavior.  Discontinue use in patients who experience suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25719, 9298, 'Semaglutide', 'Mental Disorders', 'The use of semaglutide (Wegovy) for weight loss should be avoided in patients with a history of suicidal attempts or active suicidal ideation.  Suicidal behavior and ideation have been reported in clinical trials with other weight management products.  If used, monitor patients for the emergence or worsening of depression, suicidal thoughts or behaviors, and/or any unusual changes in mood or behavior.  Discontinue use in patients who experience suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25720, 9812, 'Semaglutide', 'Mental Disorders', 'The use of semaglutide (Wegovy) for weight loss should be avoided in patients with a history of suicidal attempts or active suicidal ideation.  Suicidal behavior and ideation have been reported in clinical trials with other weight management products.  If used, monitor patients for the emergence or worsening of depression, suicidal thoughts or behaviors, and/or any unusual changes in mood or behavior.  Discontinue use in patients who experience suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25721, 13327, 'Semaglutide', 'Mental Disorders', 'The use of semaglutide (Wegovy) for weight loss should be avoided in patients with a history of suicidal attempts or active suicidal ideation.  Suicidal behavior and ideation have been reported in clinical trials with other weight management products.  If used, monitor patients for the emergence or worsening of depression, suicidal thoughts or behaviors, and/or any unusual changes in mood or behavior.  Discontinue use in patients who experience suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25722, 13583, 'Semaglutide', 'Mental Disorders', 'The use of semaglutide (Wegovy) for weight loss should be avoided in patients with a history of suicidal attempts or active suicidal ideation.  Suicidal behavior and ideation have been reported in clinical trials with other weight management products.  If used, monitor patients for the emergence or worsening of depression, suicidal thoughts or behaviors, and/or any unusual changes in mood or behavior.  Discontinue use in patients who experience suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25723, 15697, 'Semaglutide', 'Mental Disorders', 'The use of semaglutide (Wegovy) for weight loss should be avoided in patients with a history of suicidal attempts or active suicidal ideation.  Suicidal behavior and ideation have been reported in clinical trials with other weight management products.  If used, monitor patients for the emergence or worsening of depression, suicidal thoughts or behaviors, and/or any unusual changes in mood or behavior.  Discontinue use in patients who experience suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25724, 15698, 'Semaglutide', 'Mental Disorders', 'The use of semaglutide (Wegovy) for weight loss should be avoided in patients with a history of suicidal attempts or active suicidal ideation.  Suicidal behavior and ideation have been reported in clinical trials with other weight management products.  If used, monitor patients for the emergence or worsening of depression, suicidal thoughts or behaviors, and/or any unusual changes in mood or behavior.  Discontinue use in patients who experience suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25725, 84, 'Semaglutide', 'Thyroid Neoplasms', 'The use semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2).  Patients with elevated serum calcitonin or thyroid nodules noted on physical examination or neck imaging should be further evaluated.  Counsel patients regarding the potential risk for MTC with the use of semaglutide and inform them of symptoms of thyroid tumors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25726, 271, 'Semaglutide', 'Thyroid Neoplasms', 'The use semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2).  Patients with elevated serum calcitonin or thyroid nodules noted on physical examination or neck imaging should be further evaluated.  Counsel patients regarding the potential risk for MTC with the use of semaglutide and inform them of symptoms of thyroid tumors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25727, 6996, 'Semaglutide', 'Thyroid Neoplasms', 'The use semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2).  Patients with elevated serum calcitonin or thyroid nodules noted on physical examination or neck imaging should be further evaluated.  Counsel patients regarding the potential risk for MTC with the use of semaglutide and inform them of symptoms of thyroid tumors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25728, 7537, 'Semaglutide', 'Thyroid Neoplasms', 'The use semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2).  Patients with elevated serum calcitonin or thyroid nodules noted on physical examination or neck imaging should be further evaluated.  Counsel patients regarding the potential risk for MTC with the use of semaglutide and inform them of symptoms of thyroid tumors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25729, 7545, 'Semaglutide', 'Thyroid Neoplasms', 'The use semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2).  Patients with elevated serum calcitonin or thyroid nodules noted on physical examination or neck imaging should be further evaluated.  Counsel patients regarding the potential risk for MTC with the use of semaglutide and inform them of symptoms of thyroid tumors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25730, 9298, 'Semaglutide', 'Thyroid Neoplasms', 'The use semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2).  Patients with elevated serum calcitonin or thyroid nodules noted on physical examination or neck imaging should be further evaluated.  Counsel patients regarding the potential risk for MTC with the use of semaglutide and inform them of symptoms of thyroid tumors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25731, 9812, 'Semaglutide', 'Thyroid Neoplasms', 'The use semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2).  Patients with elevated serum calcitonin or thyroid nodules noted on physical examination or neck imaging should be further evaluated.  Counsel patients regarding the potential risk for MTC with the use of semaglutide and inform them of symptoms of thyroid tumors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25732, 13327, 'Semaglutide', 'Thyroid Neoplasms', 'The use semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2).  Patients with elevated serum calcitonin or thyroid nodules noted on physical examination or neck imaging should be further evaluated.  Counsel patients regarding the potential risk for MTC with the use of semaglutide and inform them of symptoms of thyroid tumors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25733, 13583, 'Semaglutide', 'Thyroid Neoplasms', 'The use semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2).  Patients with elevated serum calcitonin or thyroid nodules noted on physical examination or neck imaging should be further evaluated.  Counsel patients regarding the potential risk for MTC with the use of semaglutide and inform them of symptoms of thyroid tumors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25734, 15697, 'Semaglutide', 'Thyroid Neoplasms', 'The use semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2).  Patients with elevated serum calcitonin or thyroid nodules noted on physical examination or neck imaging should be further evaluated.  Counsel patients regarding the potential risk for MTC with the use of semaglutide and inform them of symptoms of thyroid tumors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25735, 15698, 'Semaglutide', 'Thyroid Neoplasms', 'The use semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2).  Patients with elevated serum calcitonin or thyroid nodules noted on physical examination or neck imaging should be further evaluated.  Counsel patients regarding the potential risk for MTC with the use of semaglutide and inform them of symptoms of thyroid tumors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25736, 84, 'Semaglutide', 'Gastrointestinal Diseases', 'There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis, in patients treated with GLP-1 receptor agonists, such as semaglutide.  Some events occurred without underlying renal disease, and the majority of events occurred in patients experiencing gastrointestinal reactions (nausea, vomiting, dehydration).  It is recommended to monitor renal function when initiating or escalating doses of semaglutide in patients reporting severe adverse gastrointestinal reactions.  No dose adjustment is recommended for patients with renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25737, 271, 'Semaglutide', 'Gastrointestinal Diseases', 'There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis, in patients treated with GLP-1 receptor agonists, such as semaglutide.  Some events occurred without underlying renal disease, and the majority of events occurred in patients experiencing gastrointestinal reactions (nausea, vomiting, dehydration).  It is recommended to monitor renal function when initiating or escalating doses of semaglutide in patients reporting severe adverse gastrointestinal reactions.  No dose adjustment is recommended for patients with renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25738, 6996, 'Semaglutide', 'Gastrointestinal Diseases', 'There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis, in patients treated with GLP-1 receptor agonists, such as semaglutide.  Some events occurred without underlying renal disease, and the majority of events occurred in patients experiencing gastrointestinal reactions (nausea, vomiting, dehydration).  It is recommended to monitor renal function when initiating or escalating doses of semaglutide in patients reporting severe adverse gastrointestinal reactions.  No dose adjustment is recommended for patients with renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25739, 7537, 'Semaglutide', 'Gastrointestinal Diseases', 'There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis, in patients treated with GLP-1 receptor agonists, such as semaglutide.  Some events occurred without underlying renal disease, and the majority of events occurred in patients experiencing gastrointestinal reactions (nausea, vomiting, dehydration).  It is recommended to monitor renal function when initiating or escalating doses of semaglutide in patients reporting severe adverse gastrointestinal reactions.  No dose adjustment is recommended for patients with renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25740, 7545, 'Semaglutide', 'Gastrointestinal Diseases', 'There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis, in patients treated with GLP-1 receptor agonists, such as semaglutide.  Some events occurred without underlying renal disease, and the majority of events occurred in patients experiencing gastrointestinal reactions (nausea, vomiting, dehydration).  It is recommended to monitor renal function when initiating or escalating doses of semaglutide in patients reporting severe adverse gastrointestinal reactions.  No dose adjustment is recommended for patients with renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25741, 9298, 'Semaglutide', 'Gastrointestinal Diseases', 'There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis, in patients treated with GLP-1 receptor agonists, such as semaglutide.  Some events occurred without underlying renal disease, and the majority of events occurred in patients experiencing gastrointestinal reactions (nausea, vomiting, dehydration).  It is recommended to monitor renal function when initiating or escalating doses of semaglutide in patients reporting severe adverse gastrointestinal reactions.  No dose adjustment is recommended for patients with renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25742, 9812, 'Semaglutide', 'Gastrointestinal Diseases', 'There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis, in patients treated with GLP-1 receptor agonists, such as semaglutide.  Some events occurred without underlying renal disease, and the majority of events occurred in patients experiencing gastrointestinal reactions (nausea, vomiting, dehydration).  It is recommended to monitor renal function when initiating or escalating doses of semaglutide in patients reporting severe adverse gastrointestinal reactions.  No dose adjustment is recommended for patients with renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25743, 13327, 'Semaglutide', 'Gastrointestinal Diseases', 'There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis, in patients treated with GLP-1 receptor agonists, such as semaglutide.  Some events occurred without underlying renal disease, and the majority of events occurred in patients experiencing gastrointestinal reactions (nausea, vomiting, dehydration).  It is recommended to monitor renal function when initiating or escalating doses of semaglutide in patients reporting severe adverse gastrointestinal reactions.  No dose adjustment is recommended for patients with renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25744, 13583, 'Semaglutide', 'Gastrointestinal Diseases', 'There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis, in patients treated with GLP-1 receptor agonists, such as semaglutide.  Some events occurred without underlying renal disease, and the majority of events occurred in patients experiencing gastrointestinal reactions (nausea, vomiting, dehydration).  It is recommended to monitor renal function when initiating or escalating doses of semaglutide in patients reporting severe adverse gastrointestinal reactions.  No dose adjustment is recommended for patients with renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25745, 15697, 'Semaglutide', 'Gastrointestinal Diseases', 'There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis, in patients treated with GLP-1 receptor agonists, such as semaglutide.  Some events occurred without underlying renal disease, and the majority of events occurred in patients experiencing gastrointestinal reactions (nausea, vomiting, dehydration).  It is recommended to monitor renal function when initiating or escalating doses of semaglutide in patients reporting severe adverse gastrointestinal reactions.  No dose adjustment is recommended for patients with renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25746, 15698, 'Semaglutide', 'Gastrointestinal Diseases', 'There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis, in patients treated with GLP-1 receptor agonists, such as semaglutide.  Some events occurred without underlying renal disease, and the majority of events occurred in patients experiencing gastrointestinal reactions (nausea, vomiting, dehydration).  It is recommended to monitor renal function when initiating or escalating doses of semaglutide in patients reporting severe adverse gastrointestinal reactions.  No dose adjustment is recommended for patients with renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25747, 84, 'Semaglutide', 'Hypoglycemia', 'The concomitant use of semaglutide with insulin and insulin secretagogues (e.g., sulfonylurea) may increase the risk of hypoglycemia.  It is recommended to use caution and a lower dose of insulin or insulin secretagogue may be required to minimize the risk of hypoglycemia when these agents are used in combination with semaglutide.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25748, 271, 'Semaglutide', 'Hypoglycemia', 'The concomitant use of semaglutide with insulin and insulin secretagogues (e.g., sulfonylurea) may increase the risk of hypoglycemia.  It is recommended to use caution and a lower dose of insulin or insulin secretagogue may be required to minimize the risk of hypoglycemia when these agents are used in combination with semaglutide.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25749, 6996, 'Semaglutide', 'Hypoglycemia', 'The concomitant use of semaglutide with insulin and insulin secretagogues (e.g., sulfonylurea) may increase the risk of hypoglycemia.  It is recommended to use caution and a lower dose of insulin or insulin secretagogue may be required to minimize the risk of hypoglycemia when these agents are used in combination with semaglutide.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25750, 7537, 'Semaglutide', 'Hypoglycemia', 'The concomitant use of semaglutide with insulin and insulin secretagogues (e.g., sulfonylurea) may increase the risk of hypoglycemia.  It is recommended to use caution and a lower dose of insulin or insulin secretagogue may be required to minimize the risk of hypoglycemia when these agents are used in combination with semaglutide.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25751, 7545, 'Semaglutide', 'Hypoglycemia', 'The concomitant use of semaglutide with insulin and insulin secretagogues (e.g., sulfonylurea) may increase the risk of hypoglycemia.  It is recommended to use caution and a lower dose of insulin or insulin secretagogue may be required to minimize the risk of hypoglycemia when these agents are used in combination with semaglutide.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25752, 9298, 'Semaglutide', 'Hypoglycemia', 'The concomitant use of semaglutide with insulin and insulin secretagogues (e.g., sulfonylurea) may increase the risk of hypoglycemia.  It is recommended to use caution and a lower dose of insulin or insulin secretagogue may be required to minimize the risk of hypoglycemia when these agents are used in combination with semaglutide.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25753, 9812, 'Semaglutide', 'Hypoglycemia', 'The concomitant use of semaglutide with insulin and insulin secretagogues (e.g., sulfonylurea) may increase the risk of hypoglycemia.  It is recommended to use caution and a lower dose of insulin or insulin secretagogue may be required to minimize the risk of hypoglycemia when these agents are used in combination with semaglutide.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25754, 13327, 'Semaglutide', 'Hypoglycemia', 'The concomitant use of semaglutide with insulin and insulin secretagogues (e.g., sulfonylurea) may increase the risk of hypoglycemia.  It is recommended to use caution and a lower dose of insulin or insulin secretagogue may be required to minimize the risk of hypoglycemia when these agents are used in combination with semaglutide.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25755, 13583, 'Semaglutide', 'Hypoglycemia', 'The concomitant use of semaglutide with insulin and insulin secretagogues (e.g., sulfonylurea) may increase the risk of hypoglycemia.  It is recommended to use caution and a lower dose of insulin or insulin secretagogue may be required to minimize the risk of hypoglycemia when these agents are used in combination with semaglutide.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25756, 15697, 'Semaglutide', 'Hypoglycemia', 'The concomitant use of semaglutide with insulin and insulin secretagogues (e.g., sulfonylurea) may increase the risk of hypoglycemia.  It is recommended to use caution and a lower dose of insulin or insulin secretagogue may be required to minimize the risk of hypoglycemia when these agents are used in combination with semaglutide.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25757, 15698, 'Semaglutide', 'Hypoglycemia', 'The concomitant use of semaglutide with insulin and insulin secretagogues (e.g., sulfonylurea) may increase the risk of hypoglycemia.  It is recommended to use caution and a lower dose of insulin or insulin secretagogue may be required to minimize the risk of hypoglycemia when these agents are used in combination with semaglutide.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25758, 84, 'Semaglutide', 'Pancreatitis', 'Pancreatitis has been reported with the use of semaglutide.  It is recommended to carefully observe patients for signs and symptoms of pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back and which may or may not be accompanied by vomiting) after therapy initiation.  Discontinue treatment if pancreatitis is suspected and manage as appropriate; if confirmed, do not restart treatment with semaglutide and reevaluate for appropriate treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25759, 271, 'Semaglutide', 'Pancreatitis', 'Pancreatitis has been reported with the use of semaglutide.  It is recommended to carefully observe patients for signs and symptoms of pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back and which may or may not be accompanied by vomiting) after therapy initiation.  Discontinue treatment if pancreatitis is suspected and manage as appropriate; if confirmed, do not restart treatment with semaglutide and reevaluate for appropriate treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25760, 6996, 'Semaglutide', 'Pancreatitis', 'Pancreatitis has been reported with the use of semaglutide.  It is recommended to carefully observe patients for signs and symptoms of pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back and which may or may not be accompanied by vomiting) after therapy initiation.  Discontinue treatment if pancreatitis is suspected and manage as appropriate; if confirmed, do not restart treatment with semaglutide and reevaluate for appropriate treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25761, 7537, 'Semaglutide', 'Pancreatitis', 'Pancreatitis has been reported with the use of semaglutide.  It is recommended to carefully observe patients for signs and symptoms of pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back and which may or may not be accompanied by vomiting) after therapy initiation.  Discontinue treatment if pancreatitis is suspected and manage as appropriate; if confirmed, do not restart treatment with semaglutide and reevaluate for appropriate treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25762, 7545, 'Semaglutide', 'Pancreatitis', 'Pancreatitis has been reported with the use of semaglutide.  It is recommended to carefully observe patients for signs and symptoms of pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back and which may or may not be accompanied by vomiting) after therapy initiation.  Discontinue treatment if pancreatitis is suspected and manage as appropriate; if confirmed, do not restart treatment with semaglutide and reevaluate for appropriate treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25763, 9298, 'Semaglutide', 'Pancreatitis', 'Pancreatitis has been reported with the use of semaglutide.  It is recommended to carefully observe patients for signs and symptoms of pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back and which may or may not be accompanied by vomiting) after therapy initiation.  Discontinue treatment if pancreatitis is suspected and manage as appropriate; if confirmed, do not restart treatment with semaglutide and reevaluate for appropriate treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25764, 9812, 'Semaglutide', 'Pancreatitis', 'Pancreatitis has been reported with the use of semaglutide.  It is recommended to carefully observe patients for signs and symptoms of pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back and which may or may not be accompanied by vomiting) after therapy initiation.  Discontinue treatment if pancreatitis is suspected and manage as appropriate; if confirmed, do not restart treatment with semaglutide and reevaluate for appropriate treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25765, 13327, 'Semaglutide', 'Pancreatitis', 'Pancreatitis has been reported with the use of semaglutide.  It is recommended to carefully observe patients for signs and symptoms of pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back and which may or may not be accompanied by vomiting) after therapy initiation.  Discontinue treatment if pancreatitis is suspected and manage as appropriate; if confirmed, do not restart treatment with semaglutide and reevaluate for appropriate treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25766, 13583, 'Semaglutide', 'Pancreatitis', 'Pancreatitis has been reported with the use of semaglutide.  It is recommended to carefully observe patients for signs and symptoms of pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back and which may or may not be accompanied by vomiting) after therapy initiation.  Discontinue treatment if pancreatitis is suspected and manage as appropriate; if confirmed, do not restart treatment with semaglutide and reevaluate for appropriate treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25767, 15697, 'Semaglutide', 'Pancreatitis', 'Pancreatitis has been reported with the use of semaglutide.  It is recommended to carefully observe patients for signs and symptoms of pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back and which may or may not be accompanied by vomiting) after therapy initiation.  Discontinue treatment if pancreatitis is suspected and manage as appropriate; if confirmed, do not restart treatment with semaglutide and reevaluate for appropriate treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25768, 15698, 'Semaglutide', 'Pancreatitis', 'Pancreatitis has been reported with the use of semaglutide.  It is recommended to carefully observe patients for signs and symptoms of pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back and which may or may not be accompanied by vomiting) after therapy initiation.  Discontinue treatment if pancreatitis is suspected and manage as appropriate; if confirmed, do not restart treatment with semaglutide and reevaluate for appropriate treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25769, 84, 'Semaglutide', 'Diabetic Retinopathy', 'Semaglutide should be used with caution in patients with a history of diabetic retinopathy.  Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy.  It is recommended to monitor closely for progression of diabetic retinopathy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25770, 271, 'Semaglutide', 'Diabetic Retinopathy', 'Semaglutide should be used with caution in patients with a history of diabetic retinopathy.  Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy.  It is recommended to monitor closely for progression of diabetic retinopathy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25771, 6996, 'Semaglutide', 'Diabetic Retinopathy', 'Semaglutide should be used with caution in patients with a history of diabetic retinopathy.  Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy.  It is recommended to monitor closely for progression of diabetic retinopathy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25772, 7537, 'Semaglutide', 'Diabetic Retinopathy', 'Semaglutide should be used with caution in patients with a history of diabetic retinopathy.  Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy.  It is recommended to monitor closely for progression of diabetic retinopathy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25773, 7545, 'Semaglutide', 'Diabetic Retinopathy', 'Semaglutide should be used with caution in patients with a history of diabetic retinopathy.  Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy.  It is recommended to monitor closely for progression of diabetic retinopathy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25774, 9298, 'Semaglutide', 'Diabetic Retinopathy', 'Semaglutide should be used with caution in patients with a history of diabetic retinopathy.  Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy.  It is recommended to monitor closely for progression of diabetic retinopathy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25775, 9812, 'Semaglutide', 'Diabetic Retinopathy', 'Semaglutide should be used with caution in patients with a history of diabetic retinopathy.  Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy.  It is recommended to monitor closely for progression of diabetic retinopathy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25776, 13327, 'Semaglutide', 'Diabetic Retinopathy', 'Semaglutide should be used with caution in patients with a history of diabetic retinopathy.  Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy.  It is recommended to monitor closely for progression of diabetic retinopathy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25777, 13583, 'Semaglutide', 'Diabetic Retinopathy', 'Semaglutide should be used with caution in patients with a history of diabetic retinopathy.  Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy.  It is recommended to monitor closely for progression of diabetic retinopathy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25778, 15697, 'Semaglutide', 'Diabetic Retinopathy', 'Semaglutide should be used with caution in patients with a history of diabetic retinopathy.  Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy.  It is recommended to monitor closely for progression of diabetic retinopathy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25779, 15698, 'Semaglutide', 'Diabetic Retinopathy', 'Semaglutide should be used with caution in patients with a history of diabetic retinopathy.  Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy.  It is recommended to monitor closely for progression of diabetic retinopathy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25780, 3595, 'Sodium acetate', 'Water-Electrolyte Imbalance', 'Alkalinizing agents containing sodium can induce sodium and water retention and result in hypernatremia, hypokalemia, hyperosmolality, edema and aggravation of congestive heart failure.  Therapy with sodium- containing alkalinizing agents should not be used in patients with hypernatremia or fluid retention.  Clinical monitoring of acid/base balance and electrolytes prior to, during, a following completion of therapy with alkalinizing agents is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25781, 7723, 'Sodium acetate', 'Water-Electrolyte Imbalance', 'Alkalinizing agents containing sodium can induce sodium and water retention and result in hypernatremia, hypokalemia, hyperosmolality, edema and aggravation of congestive heart failure.  Therapy with sodium- containing alkalinizing agents should not be used in patients with hypernatremia or fluid retention.  Clinical monitoring of acid/base balance and electrolytes prior to, during, a following completion of therapy with alkalinizing agents is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25782, 15668, 'Sodium acetate', 'Water-Electrolyte Imbalance', 'Alkalinizing agents containing sodium can induce sodium and water retention and result in hypernatremia, hypokalemia, hyperosmolality, edema and aggravation of congestive heart failure.  Therapy with sodium- containing alkalinizing agents should not be used in patients with hypernatremia or fluid retention.  Clinical monitoring of acid/base balance and electrolytes prior to, during, a following completion of therapy with alkalinizing agents is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25783, 3595, 'Sodium acetate', 'Acid-Base Imbalance', 'Alkalinizing agents act as proton acceptors and/or dissociate to provide bicarbonate ions.  Elimination of bicarbonate is decreased in patients with renal impairment and can result in metabolic alkalosis.  Symptoms of metabolic alkalosis include hyperirritability or tetany, arrhythmia, and/or seizures (altered pH = altered calcium), or lactic acidosis due to impaired oxygen release.  Therapy with alkalinizing agents should be administered with extreme caution in patients with compromised renal function.  Clinical monitoring of renal function, acid/base balance and electrolytes is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25784, 7723, 'Sodium acetate', 'Acid-Base Imbalance', 'Alkalinizing agents act as proton acceptors and/or dissociate to provide bicarbonate ions.  Elimination of bicarbonate is decreased in patients with renal impairment and can result in metabolic alkalosis.  Symptoms of metabolic alkalosis include hyperirritability or tetany, arrhythmia, and/or seizures (altered pH = altered calcium), or lactic acidosis due to impaired oxygen release.  Therapy with alkalinizing agents should be administered with extreme caution in patients with compromised renal function.  Clinical monitoring of renal function, acid/base balance and electrolytes is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25785, 15668, 'Sodium acetate', 'Acid-Base Imbalance', 'Alkalinizing agents act as proton acceptors and/or dissociate to provide bicarbonate ions.  Elimination of bicarbonate is decreased in patients with renal impairment and can result in metabolic alkalosis.  Symptoms of metabolic alkalosis include hyperirritability or tetany, arrhythmia, and/or seizures (altered pH = altered calcium), or lactic acidosis due to impaired oxygen release.  Therapy with alkalinizing agents should be administered with extreme caution in patients with compromised renal function.  Clinical monitoring of renal function, acid/base balance and electrolytes is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25786, 2173, 'Sitagliptin', 'Pancreatitis', 'There have been postmarketing reports of acute pancreatitis in patients taking DPP-4 inhibitors.  These drugs should be used with caution in patients with a history of pancreatitis or pancreatic disease, although it is unknown if they are at increased risk.  Patients should be observed for signs and symptoms of pancreatitis during treatment.  If pancreatitis is suspected, treatment should be discontinued immediately and appropriate management should be initiated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25787, 3965, 'Sitagliptin', 'Pancreatitis', 'There have been postmarketing reports of acute pancreatitis in patients taking DPP-4 inhibitors.  These drugs should be used with caution in patients with a history of pancreatitis or pancreatic disease, although it is unknown if they are at increased risk.  Patients should be observed for signs and symptoms of pancreatitis during treatment.  If pancreatitis is suspected, treatment should be discontinued immediately and appropriate management should be initiated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25788, 5531, 'Sitagliptin', 'Pancreatitis', 'There have been postmarketing reports of acute pancreatitis in patients taking DPP-4 inhibitors.  These drugs should be used with caution in patients with a history of pancreatitis or pancreatic disease, although it is unknown if they are at increased risk.  Patients should be observed for signs and symptoms of pancreatitis during treatment.  If pancreatitis is suspected, treatment should be discontinued immediately and appropriate management should be initiated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25789, 6706, 'Sitagliptin', 'Pancreatitis', 'There have been postmarketing reports of acute pancreatitis in patients taking DPP-4 inhibitors.  These drugs should be used with caution in patients with a history of pancreatitis or pancreatic disease, although it is unknown if they are at increased risk.  Patients should be observed for signs and symptoms of pancreatitis during treatment.  If pancreatitis is suspected, treatment should be discontinued immediately and appropriate management should be initiated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25790, 8020, 'Sitagliptin', 'Pancreatitis', 'There have been postmarketing reports of acute pancreatitis in patients taking DPP-4 inhibitors.  These drugs should be used with caution in patients with a history of pancreatitis or pancreatic disease, although it is unknown if they are at increased risk.  Patients should be observed for signs and symptoms of pancreatitis during treatment.  If pancreatitis is suspected, treatment should be discontinued immediately and appropriate management should be initiated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25791, 19852, 'Sitagliptin', 'Pancreatitis', 'There have been postmarketing reports of acute pancreatitis in patients taking DPP-4 inhibitors.  These drugs should be used with caution in patients with a history of pancreatitis or pancreatic disease, although it is unknown if they are at increased risk.  Patients should be observed for signs and symptoms of pancreatitis during treatment.  If pancreatitis is suspected, treatment should be discontinued immediately and appropriate management should be initiated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25792, 21130, 'Sitagliptin', 'Pancreatitis', 'There have been postmarketing reports of acute pancreatitis in patients taking DPP-4 inhibitors.  These drugs should be used with caution in patients with a history of pancreatitis or pancreatic disease, although it is unknown if they are at increased risk.  Patients should be observed for signs and symptoms of pancreatitis during treatment.  If pancreatitis is suspected, treatment should be discontinued immediately and appropriate management should be initiated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25793, 21131, 'Sitagliptin', 'Pancreatitis', 'There have been postmarketing reports of acute pancreatitis in patients taking DPP-4 inhibitors.  These drugs should be used with caution in patients with a history of pancreatitis or pancreatic disease, although it is unknown if they are at increased risk.  Patients should be observed for signs and symptoms of pancreatitis during treatment.  If pancreatitis is suspected, treatment should be discontinued immediately and appropriate management should be initiated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25794, 21135, 'Sitagliptin', 'Pancreatitis', 'There have been postmarketing reports of acute pancreatitis in patients taking DPP-4 inhibitors.  These drugs should be used with caution in patients with a history of pancreatitis or pancreatic disease, although it is unknown if they are at increased risk.  Patients should be observed for signs and symptoms of pancreatitis during treatment.  If pancreatitis is suspected, treatment should be discontinued immediately and appropriate management should be initiated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25795, 21141, 'Sitagliptin', 'Pancreatitis', 'There have been postmarketing reports of acute pancreatitis in patients taking DPP-4 inhibitors.  These drugs should be used with caution in patients with a history of pancreatitis or pancreatic disease, although it is unknown if they are at increased risk.  Patients should be observed for signs and symptoms of pancreatitis during treatment.  If pancreatitis is suspected, treatment should be discontinued immediately and appropriate management should be initiated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25796, 33401, 'Sitagliptin', 'Pancreatitis', 'There have been postmarketing reports of acute pancreatitis in patients taking DPP-4 inhibitors.  These drugs should be used with caution in patients with a history of pancreatitis or pancreatic disease, although it is unknown if they are at increased risk.  Patients should be observed for signs and symptoms of pancreatitis during treatment.  If pancreatitis is suspected, treatment should be discontinued immediately and appropriate management should be initiated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25797, 2173, 'Sitagliptin', 'Kidney Diseases', 'It is recommended to assess renal function prior to initiating treatment with DPP-4 inhibitors.  Patients with moderate to severe renal insufficiency and end stage renal dysfunction will require a dose adjustment.  Linagliptin will not require a dose adjustment per manufacturer''s information.  Additionally, there have been postmarketing reports of worsening renal function in some patients with renal insufficiency taking sitagliptin at inappropriate doses.  However, sitagliptin has not been found to be nephrotoxic in preclinical studies or clinical trials at appropriate doses.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25798, 3965, 'Sitagliptin', 'Kidney Diseases', 'It is recommended to assess renal function prior to initiating treatment with DPP-4 inhibitors.  Patients with moderate to severe renal insufficiency and end stage renal dysfunction will require a dose adjustment.  Linagliptin will not require a dose adjustment per manufacturer''s information.  Additionally, there have been postmarketing reports of worsening renal function in some patients with renal insufficiency taking sitagliptin at inappropriate doses.  However, sitagliptin has not been found to be nephrotoxic in preclinical studies or clinical trials at appropriate doses.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25799, 5531, 'Sitagliptin', 'Kidney Diseases', 'It is recommended to assess renal function prior to initiating treatment with DPP-4 inhibitors.  Patients with moderate to severe renal insufficiency and end stage renal dysfunction will require a dose adjustment.  Linagliptin will not require a dose adjustment per manufacturer''s information.  Additionally, there have been postmarketing reports of worsening renal function in some patients with renal insufficiency taking sitagliptin at inappropriate doses.  However, sitagliptin has not been found to be nephrotoxic in preclinical studies or clinical trials at appropriate doses.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (25800, 6706, 'Sitagliptin', 'Kidney Diseases', 'It is recommended to assess renal function prior to initiating treatment with DPP-4 inhibitors.  Patients with moderate to severe renal insufficiency and end stage renal dysfunction will require a dose adjustment.  Linagliptin will not require a dose adjustment per manufacturer''s information.  Additionally, there have been postmarketing reports of worsening renal function in some patients with renal insufficiency taking sitagliptin at inappropriate doses.  However, sitagliptin has not been found to be nephrotoxic in preclinical studies or clinical trials at appropriate doses.', '2', '', 'DDInter', 0);
